Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Muscleblind-like protein 3 (MBNL3) is an RNA-binding protein belonging to the MBNL family, which also includes MBNL1 and MBNL2. It contains two pairs of zinc finger domains that mediate direct binding to RNA, crucial for regulating alternative splicing and polyadenylation of pre-mRNAs. While MBNL1 and MBNL2 are broadly expressed and play key roles in muscle, heart, and neural tissues, MBNL3 is predominantly expressed in placental and embryonic tissues, where it orchestrates tissue-specific splicing during development. MBNL3 and other family members participate in the fine-tuning of gene expression by regulating mRNA localization, stability, maturation, and degradation. Aberrant function of the MBNL family, through loss or sequestration, is strongly implicated in the pathogenesis of myotonic dystrophy, a multisystem disorder characterized by widespread defects in alternative splicing. MBNL3’s unique tissue expression profile underpins its specialized roles in embryogenesis and placental biology, in contrast to the more ubiquitous impact of MBNL1/2.
Not applicable; no drugs target MBNL3 directly
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Muscleblind-like protein 3 (MBNL3).